Cornell Finds Diet Link to Prostate Cancer Treatment

Scientists at Weill Cornell Medicine just uncovered a hidden survival trick that prostate cancer cells use to outsmart treatment, and the solution might be hiding in plain sight on our dinner plates.

The research team found that aggressive prostate tumors rewire their metabolism to use two amino acids from protein-rich foods (isoleucine and valine) to keep growing even when hormone-blocking drugs try to stop them. This discovery explains why some prostate cancers develop resistance to enzalutamide, a common treatment that blocks the male hormones fueling tumor growth.

Lead researcher Zhongchi Li noticed that aggressive tumors had elevated levels of a compound called propionylcarnitine. Following that clue, the team discovered that when cancer cells break down isoleucine and valine, they produce propionyl-CoA, which acts like a master switch keeping cholesterol production turned on.

Here's why that matters: prostate cancer cells use that excess cholesterol to make their own testosterone and related hormones, essentially creating a workaround when drugs block their normal hormone supply. It's like the tumor building its own fuel factory when the main pipeline gets shut down.

The research revealed something even more fascinating. When the scientists restricted isoleucine and valine in mouse models, tumor growth slowed and cancer spread to the lungs decreased significantly. Boosting those amino acids had the opposite effect, promoting faster tumor growth.

Why This Inspires

This discovery gives doctors multiple new ways to fight back against resistant prostate cancer. Scientists can now explore whether carefully controlled diets lower in these specific amino acids might boost the effectiveness of existing drugs.

The research also helps explain a medical mystery: why cholesterol-lowering statins help some prostate cancer patients but not others. If this pathway is active in a patient's tumor, statins might provide extra benefit alongside standard treatment.

Senior author John Blenis emphasizes that this pathway connects nutrients, cholesterol, and hormone signaling, creating several potential intervention points. His team is already exploring whether drugs that block the enzymes converting these amino acids into propionyl-CoA could prevent treatment resistance.

The findings extend beyond just prostate cancer. Because this metabolic pathway plays a role in how cells respond to nutrient availability, it could have implications for other cancers, aging, and metabolic diseases.

For the 300,000 American men diagnosed with prostate cancer each year, this research offers something precious: hope that when first-line treatments stop working, science might have new answers waiting in the pipeline.

Future clinical trials will determine whether dietary strategies are safe and effective for patients, but the preclinical results suggest a promising new frontier where personalized nutrition could work hand-in-hand with cutting-edge medicine to save lives.